All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hubAML HubGVhD HubLymphoma HubMPN HubMultiple Myeloma Hub
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert Opinions

Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

By Becky Lowe, Jack Bear, Paola Frisone
Featured
Uwe Platzbecker
Jan 12, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

In this video, Platzbecker reports the promising data, presented at ASH 2020, on the telomerase inhibitor imetelstat.

Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

 

Share:
More about...
ASHASH 2020ImetelstatMyelodysplastic syndromes

Related articles

Newsletter

Subscribe to get the best content related to MDS delivered to your inbox